Ezalife Clinical Trial Shows 77% Reduction in Feeding Tube Dislodgement with Button Huggie® Device

Ezalife announced compelling clinical results demonstrating that its Button Huggie® device achieved a 77% reduction in feeding tube dislodgement, addressing a long-standing challenge in patient care. Feeding tubes, commonly secured with tape and gauze, have remained largely unchanged for decades, often leading to discomfort, complications, and emergency interventions. Ezalife’s solution introduces a purpose-built, FDA-registered device designed to stabilize G-buttons more effectively.

In addition to clinical improvements, EzaLife reported strong patient and caregiver satisfaction metrics including approximately 270% increase in parent satisfaction compared to traditional methods and a Net Promoter Score of 76, significantly higher than the industry average of 46. "These results highlight both the clinical effectiveness and the real-world impact on families," the company stated. "We’re not just improving outcomes; we’re improving daily life."

The Button Huggie® is protected by a granted U.S. patent with 18 claims, along with additional international patents across Europe, the UK, Canada, China, and Japan, reinforcing Ezalife’s position as a category innovator. By addressing a critical yet underserved segment of the $1.9 billion feeding tube market, Ezalife is positioning itself as a disruptive force in post-operative and long-term care.

As its StartEngine campaign approaches its April 6 close, the company continues to attract attention from investors seeking opportunities at the intersection of healthcare innovation and proven clinical validation. The clinical results matter because feeding tube dislodgement represents a significant patient safety issue that can lead to serious complications, increased healthcare costs, and diminished quality of life for patients who rely on these devices for nutrition and medication administration.

The implications of this announcement extend beyond the immediate clinical benefits to potentially transform standard of care practices that have seen minimal innovation for decades. The combination of strong clinical data with exceptional patient satisfaction metrics suggests this technology could see rapid adoption in both hospital and home care settings. Furthermore, the timing of these results coincides with the company's fundraising efforts, potentially accelerating market penetration and development of additional patient-centered solutions.